Tarsus Pharmaceuticals Inc (TARS)
38.22
-0.36
(-0.93%)
USD |
NASDAQ |
May 17, 16:00
38.22
0.00 (0.00%)
After-Hours: 16:09
Tarsus Pharmaceuticals Gross Profit Margin (Quarterly): 94.01% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 94.01% |
| December 31, 2023 | 90.70% |
| September 30, 2023 | 79.85% |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 96.00% |
| September 30, 2022 |
| Date | Value |
|---|---|
| June 30, 2022 | 96.58% |
| March 31, 2022 | 93.88% |
| December 31, 2021 | |
| September 30, 2021 | 94.76% |
| June 30, 2021 | 96.65% |
| March 31, 2021 | 96.12% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
79.85%
Minimum
Sep 2023
96.65%
Maximum
Jun 2021
93.17%
Average
94.76%
Median
Sep 2021
Gross Profit Margin (Quarterly) Benchmarks
| Pacira BioSciences Inc | 71.63% |
| Unicycive Therapeutics Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 81.54% |
| IGC Pharma Inc | 65.20% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -73.59% |
| Return on Assets | -57.75% |
| Return on Invested Capital | -64.69% |
| Profit Margin (Quarterly) | -129.4% |
| Operating Margin (Quarterly) | -136.5% |
| Return on Net Operating Assets | -599.6% |